The Central Commission for Discipline Inspection again: the credit evaluation system makes the briber pay a huge price

On October 17th, the website of the Central Commission for Discipline Inspection published the article "Strictly checking the transaction of power and money, establishing a list of disrelievers, concentrating on volume procurement, and cutting off the chain of medical bribery benefits", which refers directly to improper transactions between medical representatives and medical institutions.
Recently, a video on the website of the State Supervision Commission of the Central Commission for Discipline Inspection exposed the details of the bribery case in which Wang Xiaojun, a former pharmacy staff member of the First People's Hospital in Hangzhou City, Zhejiang Province, used his position to facilitate the introduction of new drugs, drug procurement and other aspects for the benefit of drug dealers and illegally received kickbacks of more than 10.19 million yuan.
, only injection of sodium cephalosporine and other two drugs for Wang Xiaojun and others brought up to 3.25 million yuan of "benefits."
drugmakers said Mr Wang charged rebates of up to 40 per cent of the drug's retail price.
in addition to the huge amount involved in the case, corruption is increasingly hidden, in recent years, the investigation of medical bribery cases also show the characteristics of multi-participation.
A recent judgment published by the China Referee Papers Network shows that Chen Jianchang, former director of cardiovascular medicine at the Second Hospital affiliated with Suzhou University in Jiangsu Province, used his position to provide support and assistance for the sale, use and use of medical supplies by a number of companies, and received a total of 3.22 million yuan from the actual head of the above-mentioned company.
, Mr. Yan also paid bribes to other members of the department through Chen Jianchang, amounting to 2.79 million yuan.
receive rebates for medicines and medical supplies, which is a common form of pharmaceutical bribery.
are explicit, such as cash transfers, and some are implicit, such as giving gifts, subsidizing travel, etc.
bribery and bribery are two sides of medical corruption, but in the investigation of medical corruption cases, it is often the briber accepted the law sanctions, the price paid by the briber is almost negligible.
compared with the huge benefits of bribery, its low "cost" so that many pharmaceutical companies in the East Window incident is still my own, repeated bribery, while paying bribes to many people from time to time.
Against the briber, the State Health Insurance Administration has issued the Guidance on the Establishment of a Credit Evaluation System for Pharmaceutical Prices and Recruitment, requiring all localities to establish and implement a credit evaluation system by the end of 2020, and pharmaceutical enterprises involved in seven kinds of mis-trusting acts, such as commercial bribery of pharmaceuticals, will be included in the "black list" of disrelieving.
Pharmaceutical enterprises will face written warnings, relying on centralized procurement platform to the purchaser to prompt risk information, limit or suspend the relevant drugs or medical supplies hanging network, limit or suspend the procurement of related drugs or medical supplies, disclosure of disin facts and other disposal measures, misinreination involving the number of provinces to meet the prescribed conditions, will also be initiated by the State Health Insurance Administration pharmaceutical prices and tender procurement guidance center national joint disposal.
In this way, drugs, equipment supplies rebates, interest export and other industries in the general sub-rules, now become a collection, hanging network procurement obstacles, to give rebates will lead to the loss of access to the centralized procurement market.
days when drug companies and drug companies lay down to make money.
the establishment of credit evaluation system for pharmaceutical companies, there are a series of "big moves" in the medical field recently.
national drug collection as an example has moved towards normal operation, drug collection has been carried out in three batches, involving a total of 112 varieties, an average decline of 54%, drug prices falsely high moisture was greatly squeezed out.
September 14, the state organized the central procurement and use of high-value medical supplies start-up meeting held in Tianjin, marking that after the centralized procurement of drugs, high-value medical supplies represented by the crown vein stent will also enter the era of strip procurement. Chen Jinfu, deputy director of the State Health Insurance Administration, said:
Resuming the impact of the original sales model on the development of China's industry, and truly through cost competition, quality competition, innovation, to promote scale development, advantage development."
of September, the State Health and Welfare Commission, together with relevant departments, organized comprehensive supervision and supervision of the medical and health industry, and conducted field inspections of 19 provinces (regions, cities) and Xinjiang Production and Construction Corps, including Beijing and Hebei.
inspection team mainly solicits five aspects of the drug field commercial bribery and other clues, which are representative of the problem clues, in the field inspection to carry out spot checks and verification, timely response to social concerns.
September 30, the State Drug Administration organized the development of the "Pharmaceutical Representative Filing Management Measures (Trial)" was announced to the public.
clearly stated that pharmaceutical representatives shall not undertake the task of drug sales, implement collection and processing of purchase and sale bills and other sales behavior.
In addition, the document clearly defines the main tasks of pharmaceutical representatives, including four aspects: formulating plans and programs for the promotion of pharmaceutical products, transmitting relevant information on pharmaceutical products to medical personnel, assisting medical personnel in the rational use of pharmaceutical products of the enterprise, and collecting and feedback on the clinical use of pharmaceutical products and hospital needs.
in order to completely cut off the drug supplies rebate interest chain, in the country to fight a series of anti-drug prices falsely high combination punch.
the gray chain of interests be completely cut off? At present, the industry seems to have several changes: 1, a number of enterprises to lay off staff, personnel optimization.
collection mode to reduce the cost of sales by ensuring the clinical use of selected drugs, to help pharmaceutical companies abandon the traditional marketing model.
huge sales team became the first to "open the knife" object.
2019 annual report, the number of sales staff at Xinlitai fell by about 20% from 2,108 at the end of 2018 to 1,666.
and this year's annual report is likely to change even more.
2, research and development investment increased.
pharmaceutical companies are also putting more energy into research and development.
data show that Hengrui, Fosun, China Bio, Stone Pharmaceuticals, Shanghai Pharmaceuticals, Colum and other leading enterprises, the 2019 research and development threshold of more than 1 billion yuan, compared with previous years, have different degrees of growth.
3, the pharmaceutical generation is facing transformation.
for a long time, pharmaceutical representatives gradually expanded from the initial academic promotion to product sales, and the resulting "kickback scandal" between pharmaceutical representatives and doctors has also been criticized in recent years.
, the pharmaceutical representative's content and qualifications with the standardization of the industry, is gradually returning to its original value.